Serum total IgE as immunological marker in patients with chronic hepatitis B Virus infection, and hepatitis B related hepatocellular carcinoma |
The Egyptian Journal of Immunology Volume 30 (1), January, 2023 Pages: 96–104. www.Ejimmunology.org https://doi.org/10.55133/eji.300110 |
|
Mohammed Khalil1, Abeer Sharaf Eldin3, Ahmed Sadek2, Bahaa M. Badr1 and Ayman S. Yassin1 |
1Department of Medical Microbiology & Immunology, Faculty of Medicine, Al-Azhar University (Assiut branch), Assiut, Egypt.
2Department of Medical Microbiology & Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt. 3Department of Tropical Medicine & Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt. |
Corresponding author: Mohammed Khalil, Department of Medical Microbiology & Immunology, Faculty of Medicine, Al-Azhar University (Assiut branch), Assiut, Egypt. Email: mhmd22ali_ali@yahoo.com. |
Abstract
This study evaluated the efficacy of IgE in predicting disease progression in chronic hepatitis B virus (HBV) and HBV related hepatocellular carcinoma (HCC) compared to normal controls. The study included 60 HBV-infected patients. Of these, 30 patients with chronic hepatitis B but not related to HCC and 30 patients with related HCC. Serum level of IgE was measured by ELISA. Serum level of IgE was higher in HCC patients than non-HCC patients (p< 0.005). Significant correlations were detected between IgE, transaminases (ALT, AST), alpha-fetoprotein and severity scores in chronic hepatitis B (CHB) patients. The level of IgE was correlated with HB viral load. Stronger correlations were evident between IgE, prothrombin time and total bilirubin. In conclusion, IgE levels may be considered as non-invasive markers for monitoring liver disease progression in CHB.
Keywords: Hepatitis-B Virus, Hepatocellular carcinoma, Immunoglobulin-E.
Date received: 29 September 2022; accepted: 29 November 2022
PMID: 36592385
Full Text